Cargando…

Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey

BACKGROUND: COVID-19 and lysosomal storage disorders (LSDs) share a common immunological pathway as they cause the release of cytokines in a similar pattern. We aimed to evaluate the immunity status and reveal the course of COVID-19 in patients with LSDs. RESULTS: The median age of 110 patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kilavuz, S., Kor, D., Bulut, F.D., Serbes, M., Karagoz, D., Altıntas, D.U., Bisgin, A., Seydaoğlu, G., Mungan, H.N.O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	French Society of Pediatrics. Published by Elsevier Masson SAS. 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125140/ https://www.ncbi.nlm.nih.gov/pubmed/35705384 http://dx.doi.org/10.1016/j.arcped.2022.05.003

Ejemplares similares

Morquio A syndrome and effect of enzyme replacement therapy in different age groups of Turkish patients: a case series
por: Kılavuz, Sebile, et al.
Publicado: (2021)

Clinical and molecular findings in 37 Turkish patients with isolated methylmalonic acidemia
por: ŞEKER YILMAZ, Berna, et al.
Publicado: (2021)

Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey
por: Balcı, Sibel, et al.
Publicado: (2020)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Pain in adult patients with Pompe disease
por: Karabul, N., et al.
Publicado: (2014)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS)
por: Zimran, Ari, et al.
Publicado: (2017)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
por: Schwartz, Ida Vanessa D., et al.
Publicado: (2017)

Genetic and clinical characteristics of Filipino patients with Gaucher disease
por: Chiong, Mary Anne D., et al.
Publicado: (2018)

Exodontia in patient with Gaucher's disease
por: Lisboa, Guacyra Machado, et al.
Publicado: (2011)

Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
por: Revel-Vilk, Shoshana, et al.
Publicado: (2023)

Differentiating children with familial Mediterranean fever from other recurrent fever syndromes: The utility of new Eurofever/PRINTO classification criteria
por: Kışla Ekinci, Rabia Miray, et al.
Publicado: (2021)

Genetic counseling in Pompe disease
por: Taglia, Antonella, et al.
Publicado: (2011)

Panorama
por: HNO, Ressort
Publicado: (2020)

Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey
por: Bozdogan, Sevcan Tug, et al.
Publicado: (2021)

Cytokines in treated and untreated Pompe patients
por: Karabul, N, et al.
Publicado: (2013)

Precocious puberty in patients with Pompe disease
por: Tsai, Meng-Ju Melody, et al.
Publicado: (2023)

Clinical Outcomes of Patients with Chronic Neuropathic Form of Gaucher Disease in the Spanish Real-World Setting: A Retrospective Study
por: Stanescu, Sinziana, et al.
Publicado: (2023)

233 The Evaluation of Allergen Sensitivity in Allergic Rhinoconjunctivitis and Allergic Asthma Patients in Antalya, Turkey
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Dental profile of patients with Gaucher disease
por: Fischman, Stuart L, et al.
Publicado: (2003)

Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry
por: Nguyen, Yann, et al.
Publicado: (2020)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

“Double-Trouble” for Respiratory Control in Pompe Disease
por: O'Halloran, Ken D.
Publicado: (2011)

Pompes turbomoleculaires
por: Versolatto, B
Publicado: (1982)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Development of a disease severity scoring system for patients with Pompe disease
por: Giannini, E, et al.
Publicado: (2008)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Clinical Analysis of Algerian Patients with Pompe Disease
por: Sifi, Y., et al.
Publicado: (2017)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS)
por: Stepien, Karolina M., et al.
Publicado: (2020)

Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences
por: Chien, Yin-Hsiu, et al.
Publicado: (2020)

Characteristics of Pompe disease in China: a report from the Pompe registry
por: Zhao, Yuying, et al.
Publicado: (2019)

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
por: Dardis, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kk6eedaoc4uahabt12qo5rsfkm